Compact

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into therapeutic products. Solving the bottleneck of BP delivery is one of the main incentives of the pharmaceutical industry as this would allow a broadening of the spectrum of potential targets for therapeutic intervention needed to fill their drug pipelines. COMPACT represents Europe's frontrunners in pharmaceutics, nanotechnology, biology, chemistry, engineering and imaging who will work in close collaboration with EFPIA on the delivery issues with BP. The main objectives are (1) to identify and understand transport pathways across biological barriers and cell membranes that can be utilized for delivery of BP, (2) to c

1 November 2012

31 October 2017

FP7

7.A.SP1

JTI

Joint Technology Initiatives (Annex IV-SP1)